Citations

Clear

4847 citation(s) found for "Tu, Eric".

Ligation of the Dorsal Venous Complex in a Robot-Assisted Radical Prostatectomy
Wisenbaugh, Eric S., Andrews, Paul E. , Castle, Erik P.

Mayo Clinic

Videourology™ | December 10, 2013 | Volume: 28 | Issue: 2 | Pages: No page available

10.1089/vid.2013.0079 Get It

SAGE-Journals-Accessible-Video-Player 10.1089/vid.2013.0079.M1 sj-vid-1-vid-10.1089_vid.2013.0079
Influence of Conventional Cardiovascular Risk Factors and Lifestyle Characteristics on Cardiovascular Disease After Hematopoietic Cell Transplantation
Chow, Eric J. , Lee, Stephanie J. , Cushing‐Haugen, Kara L. , Inamoto, Yoshihiro , Khera, Nandita , Leisenring, Wendy M. , Syrjala, Karen L. , Baker, Kevin Scott , Flowers, Mary E.D. , Martin, Paul J. , Leisenring, Wendy , Chow, Eric J , Lee, Stephanie J

Mayo Clinic

Journal of Clinical Oncology | December 3, 2013 | Volume: 32 | Issue: 3 | Pages: 191-198

10.1200/jco.2013.52.6582 | PMID 24297944 Get It

Purpose To determine the influence of modifiable lifestyle factors on the risk of cardiovascular disease after hematopoietic cell transplantation (HCT). Patients and Methods HCT survivors of ≥ 1 year treated from 1970 to 2010 (n = 3,833) were surveyed from 2010 to 2011 on current cardiovascular health and related lifestyle factors (smoking, diet, recreational physical activity). Responses (n = 2,362) were compared with those from a matched general population sample (National Health and Nutrition Examination Survey [NHANES]; n = 1,192). Results Compared with NHANES participants, HCT survivors (median age, 55.9 years; median 10.8 years since HCT; 71.3% allogeneic) had higher rates of cardiomyopathy (4.0% v 2.6%), stroke (4.8% v 3.3%), dyslipidemia (33.9% v 22.3%), and diabetes (14.3% v 11.7%; P < .05 for all comparisons). Prevalence of hypertension was similar (27.9% v 30.0%), and survivors were less likely to have ischemic heart disease (6.1% v 8.9%; P < .01). Among HCT survivors, hypertension, dyslipidemia, and diabetes were independent risk factors for ischemic heart disease and cardiomyopathy, and smoking was associated with ischemic heart disease and diabetes (odds ratios [ORs], 1.8 to 2.1; P = .02). Obesity was a risk factor for post-transplantation hypertension, dyslipidemia, and diabetes (ORs ≥ 2.0; P < .001). In contrast, lower fruit/vegetable intake was associated with greater risk of dyslipidemia and diabetes (ORs, 1.4 to 1.8; P ≤ .01), and lower physical activity level was associated with greater risk of hypertension and diabetes (ORs, 1.4 to 1.5; P < .05). Healthier lifestyle characteristics among HCT survivors attenuated risk of all cardiovascular conditions assessed. Conclusion Attention of clinicians to conventional cardiovascular risk factors and modifiable lifestyle characteristics offers hope of reducing serious cardiovascular morbidity after HCT.
Primary Sjögren's syndrome 1976–2005 and associated interstitial lung disease: a population-based study of incidence and mortality
Nannini, Carlotta, Jebakumar, Adlene J, Crowson, Cynthia S. , Ryu, Jay H. , Matteson, Eric L. , Ryu, Jay H

Mayo Clinic

BMJ Open | November 26, 2013 | Volume: 3 | Issue: 11 | Pages: e003569

10.1136/bmjopen-2013-003569 | PMID 24282246 Get It

Objective A very few studies describe the epidemiology of primary Sjögren's syndrome (pSS). The reported frequency of pulmonary involvement in pSS varies widely depending on the detection method employed, and consists mainly of various forms of airways disease. We aimed to evaluate the incidence and mortality of pSS and of lung disease in pSS, focusing on interstitial lung disease (ILD). Methods A population-based incidence cohort of patients diagnosed with pSS in 1976–2005 was assembled. Diagnosis was based on the 2002 American-European Consensus Group criteria for pSS. Cumulative incidence adjusted for the competing risk of death was estimated. A Cox model with a time-dependent covariate was used to determine the incidence and the standardised mortality HR of pSS. Results 85 patients with pSS were identified (mean age 59.9 years; 91% women). The annual incidence of pSS was 4.2, 95% CI (3.3 to 5.1)/100 000 population and it increased with higher age at pSS diagnosis (18–44 years: 2.1/100 000 vs ≥75 years: 12.3/100 000). Standardised mortality ratio in pSS compared with the general population was 0.92, 95% CI (0.57 to 1.41). A total of 105 patients with pSS and ILD were identified (mean age 58.1 years; 91% women). Among patients with pSS without prior ILD, the cumulative incidence of ILD in patients with pSS was 10% (±3%) at 1 year after diagnosis of pSS and increased to 20% (±4%) by 5 years after pSS. The development of lung disease in pSS was associated with poor survival (HR 2.16; 95% CI 0.99 to 4.74). Conclusions pSS incidence seems to be almost the same as was reported in a previous study conducted among Olmsted County Minnesota population. Survival among patients with pSS and general population does not differ substantially. However, patients with pSS who have ILD likely have increased premature mortality.
Thyrotropin Secretion in Healthy Subjects Is Robust and Independent of Age and Gender, and Only Weakly Dependent on Body Mass Index
Roelfsema, Ferdinand , Pijl, Hanno , Kok, Petra, Endert, Erik , Fliers, Eric , Pereira, Alberto M. , Veldhuis, Johannes D. , Biermasz, Nienke Ruurdje

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 26, 2013 | Volume: 99 | Issue: 2 | Pages: 570-578

10.1210/jc.2013-2858 | PMID 24276453 Get It

Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Holmes, DaJuanicia N. , Piccini, Jonathan P. , Ansell, Jack , Chang, Paul, Mahaffey, Kenneth W. , Kowey, Peter R. , Ezekowitz, Michael D. , Singer, Daniel E. , Thomas, Laine , Patients, The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and, Steinberg, Benjamin A. , Fonarow, Gregg C. , Gersh, Bernard J. , Peterson, Eric D. , Hylek, Elaine M. , Patients, The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Investigators and

Mayo Clinic

Journal of the American Heart Association | November 26, 2013 | Volume: 2 | Issue: 6 | Pages: No page available

10.1161/jaha.113.000535 | PMID 24275632 Get It

Background Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. Methods and Results We studied patterns of dabigatran use among patients enrolled in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF) Registry between June 2010 and August 2011 and followed for 12 months. Among 9974 atrial fibrillation patients included, 1217 (12%) were treated with dabigatran during the study. Overall, patients receiving dabigatran were younger (median age 72 versus 75 years, P <0.0001), more likely to be white (92% versus 89%, P =0.005), more likely to have private insurance (33% versus 25%, P <0.0001), and less likely to have prior cardiovascular disease (4% versus 33%, P <0.0001). They had more new‐onset atrial fibrillation (8.8% versus 4.1%, P <0.0001), lower CHADS 2 scores (estimated risk based on the presence of congestive heart failure, hypertension, aged ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack; mean 2.0 versus 2.3, P <0.0001), and lower Anticoagulation and Risk Factors in Atrial Fibrillation scores (mean 2.4 versus 2.8, P <0.0001). More than half (n=14/25, 56%) of patients with severe kidney disease were not prescribed reduced dosing, whereas 10% (n=91/920) with preserved renal function received lower dosing. Among patients not on dabigatran at baseline, 8% had dabigatran initiated during follow‐up. Patient education was significantly associated with switching from warfarin to dabigatran (adjusted odds ratio for postgraduate 1.73, P =0.007), whereas antiarrhythmic drug use significantly correlated with de novo adoption of dabigatran (adjusted odds ratio 2.4, P <0.0001). Conclusions Patients receiving dabigatran were younger and at a lower risk of stroke and bleeding. Patients appeared to drive switching from warfarin, whereas clinical characteristics influenced de novo start of dabigatran. These data suggest cautious early uptake of dabigatran, and more careful attention to dosing adjustments is warranted. Clinical Trial Registration URL : Clinicaltrials.gov. Unique identifier: NCT 01165710.
Fibrin Glue to Treat Spinal Fluid Leaks Associated with Intrathecal Drug Systems
Freeman, Eric D., Hoelzer, Bryan C. , Eldrige, Jason S. , Moeschler, Susan M.

Mayo Clinic

Pain Practice | November 21, 2013 | Volume: 14 | Issue: 6 | Pages: 570-576

10.1111/papr.12151 | PMID 24256213 Get It

AbstractIntrathecal drug delivery systems (IDDSs) are used to treat resistant pain states as well as intractable spasticity via medication delivery into the spinal fluid. Risks associated with implantation of these devices include infection, bleeding, intrathecal granuloma formation, and neurologic sequelae similar to other neuraxial procedures. Intrathecal catheter placement creates the additional risk of persistent spinal fluid leak, which can lead to postdural puncture headaches as well as seroma formation and may require subsequent surgical exploration or explantation. This retrospective case series examines 3 patients at a single institution with persistent spinal fluid leak after IDDS placement (and explantation in one case) resulting in headache and/or seroma formation that were treated with epidural fibrin glue.Three patients underwent IDDS implantation with baclofen for spasticity. In 1 patient, a cerebral spinal fluid leak developed at 1‐week postoperatively. After several unsuccessful epidural blood patches and surgical exploration with a catheter revision, she was ultimately treated successfully with a fibrin glue patch. The second patient received an IDDS and did well until a seroma developed 1 year later. He was likewise treated with an epidural fibrin glue patch after 2 failed blood patches. In a third patient, a spinal fluid leak developed after explantation of an IDDS and was treated with an epidural fibrin glue patch as initial therapy.
Asymptomatic lambert–eaton syndrome
Denys, Eric H., Lennon, Vanda A.

Mayo Clinic

Muscle & Nerve | November 21, 2013 | Volume: 49 | Issue: 5 | Pages: 764-767

10.1002/mus.24126 | PMID 24259319 Get It

ABSTRACTIntroductionAll descriptions of the Lambert–Eaton syndrome are based on symptomatic patients. We incidentally encountered electromyographic evidence of this syndrome in a patient being studied for another reason. The patient had controlled hypothyroidism and smoked for 9 pack‐years but never had symptoms of weakness or had evidence of cancer. Methods: Detailed electrophysiological and serological evaluations were undertaken in this study. Results: Neuromuscular transmission tests were consistent with a presynaptic disorder. Autoantibodies specific for P/Q‐type voltage‐gated calcium channels (VGCC) were detected in the serum and persisted throughout 7 years of follow‐up. Multiple IgG markers of thyrogastric autoimmunity also were detected. Conclusions: This demonstration of asymptomatic Lambert–Eaton syndrome persisting for 8 years provided novel insight into the natural history of the disorder. It is plausible that patients with a subclinical syndrome would have abrupt neuromuscular decompensation when challenged with medications that compromise the safety factor for synaptic transmission. Muscle Nerve 49: 764–767, 2014
Telemedicine Barriers Associated with Regional Quality Measures
North, Frederick , Crane, Sarah J. , Takahashi, Paul Y. , Ward, William J. , Tulledge‐Scheitel, Sidna M. , Ytterberg, Karen L., Tangalos, Eric G., Stroebel, Robert J. , Takahashi, Paul

Mayo Clinic

Telemedicine and e-Health | November 9, 2013 | Volume: 20 | Issue: 2 | Pages: 179-181

10.1089/tmj.2013.0167 | PMID 24205836 Get It

Telemedicine practitioners are familiar with multiple barriers to delivering care at a distance. Licensing and reimbursement barriers are well known and are being addressed at national and state levels by the American Telemedicine Association. Another telemedicine barrier comes in the form of quality measures for diabetes. Minnesota medical practices are currently being compared on the proportion of their patients with diabetes who have attained goals for blood pressure, low-density lipoprotein cholesterol, and hemoglobin A1C. The quality measure for blood pressure specifically excludes measurements taken by the patient, thus precluding blood pressure telemonitoring as a way to meet the blood pressure goal. To counter this barrier, advocacy in telemedicine is needed so that telemonitoring as a data collection tool is included in quality measures.
Irritable bowel syndrome-diarrhea: characterization of genotype by exome sequencing, and phenotypes of bile acid synthesis and colonic transit
Camilleri, Michael , Klee, Eric W. , Shin, Andrea , Carlson, Paula, Grover, Madhusudan , Zinsmeister, Alan R., Li, Ying

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | November 8, 2013 | Volume: 306 | Issue: 1 | Pages: G13-G26

10.1152/ajpgi.00294.2013 | PMID 24200957 Get It

The study objectives were: to mine the complete exome to identify putative rare single nucleotide variants (SNVs) associated with irritable bowel syndrome (IBS)-diarrhea (IBS-D) phenotype, to assess genes that regulate bile acids in IBS-D, and to explore univariate associations of SNVs with symptom phenotype and quantitative traits in an independent IBS cohort. Using principal components analysis, we identified two groups of IBS-D ( n = 16) with increased fecal bile acids: rapid colonic transit or high bile acids synthesis. DNA was sequenced in depth, analyzing SNVs in bile acid genes ( ASBT, FXR, OSTα/β, FGF19, FGFR4, KLB, SHP, CYP7A1, LRH-1, and FABP6). Exome findings were compared with those of 50 similar ethnicity controls. We assessed univariate associations of each SNV with quantitative traits and a principal components analysis and associations between SNVs in KLB and FGFR4 and symptom phenotype in 405 IBS, 228 controls and colonic transit in 70 IBS-D, 71 IBS-constipation. Mining the complete exome did not reveal significant associations with IBS-D over controls. There were 54 SNVs in 10 of 11 bile acid-regulating genes, with no SNVs in FGF19; 15 nonsynonymous SNVs were identified in similar proportions of IBS-D and controls. Variations in KLB (rs1015450, downstream) and FGFR4 [rs434434 (intronic), rs1966265, and rs351855 (nonsynonymous)] were associated with colonic transit (rs1966265; P = 0.043), fecal bile acids (rs1015450; P = 0.064), and principal components analysis groups (all 3 FGFR4 SNVs; P < 0.05). In the 633-person cohort, FGFR4 rs434434 was associated with symptom phenotype ( P = 0.027) and rs1966265 with 24-h colonic transit ( P = 0.066). Thus exome sequencing identified additional variants in KLB and FGFR4 associated with bile acids or colonic transit in IBS-D.
Immunological and Mass Spectrometric Assays of SHBG: Consistent and Inconsistent Metabolic Associations in Healthy Men
Veldhuis, Johannes D. , Bondar, Olga P., Dyer, Roy B. , Trushin, Sergey A., Klee, Eric W. , Klee, George G., Singh, Ravinder J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | November 8, 2013 | Volume: 99 | Issue: 1 | Pages: 184-193

10.1210/jc.2013-2642 | PMID 24203061 Get It